We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strategic Partnerships Power Tempus AI's Healthcare Expansion
Read MoreHide Full Article
Key Takeaways
Tempus partnered with Northwestern to use its Lens platform in Alzheimer's genomic research.
TEM teamed up with Boehringer Ingelheim to expand cancer pipeline research using AI insights.
Tempus also collaborated with Stemline and Genialis to advance oncology treatments with AI platforms.
Tempus AI, Inc. (TEM - Free Report) is rapidly expanding its partnerships across oncology and neuroscience, leveraging its AI platforms — Lens and Next — to accelerate precision medicine.
Tempus has entered into a multi-year collaboration with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine to use Tempus’ AI-powered Lens platform for analyzing and restructuring genomic data in Alzheimer’s research. In February, Tempus also partnered with the Institute for Follicular Lymphoma Innovation to create a real-world, multimodal, deidentified FL data library in Lens, enabling AI-driven insights to accelerate follicular lymphoma treatment development and improve patient outcomes.
Meanwhile, in May, Tempus made a new strategic collaboration with Boehringer Ingelheim to advance the latter’s cancer pipeline, building on prior joint work that leveraged data and AI to drive therapeutic research and development. Furthermore, earlier this year, Tempus and Stemline Therapeutics, a Menarini Group subsidiary, announced a collaboration to advance oncology treatments. The partnership will leverage Tempus’ AI-enabled Next platform to help clinicians identify when an ESR1 test may be appropriate.
In January, Tempus joined forces with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types.
TEM’s Peers Driving Growth Through Collabs
Sophia Genetics (SOPH - Free Report) expanded its partnership with AstraZeneca (AZN - Free Report) in a multi-year collaboration to use Sophia Genetics’ multimodal AI Factories for generating evidence on breast cancer therapies’ efficacy, value and real-world impact. It will also support the development of a bespoke AI-powered predictive model to optimize outcome for patients undergoing treatment for breast cancer. Additionally, Sophia Genetics expanded its collaboration with Result Laboratorium, a leading Dutch clinical lab, to advance pharmacogenomics (PGx) insights across the region using the Sophia DDM Platform and Sophia DDM Dispatch.
AbbVie (ABBV - Free Report) announced a collaboration and license option agreement with ADARx Pharmaceuticals, a late clinical-stage biotechnology company, to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology. AbbVie also inked a license agreement with Gubra A/S to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.
TEM Stock Outperforms Industry & Benchmark
In the past year, Tempus AI shares have surged 35.9%, outperforming the industry’s 21.4% growth and the S&P 500 composite’s 15.9% improvement.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 9.38X compared with the industry average of 5.87X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's loss per share estimate has shown mixed movements for 2025 and 2026.
Image: Bigstock
Strategic Partnerships Power Tempus AI's Healthcare Expansion
Key Takeaways
Tempus AI, Inc. (TEM - Free Report) is rapidly expanding its partnerships across oncology and neuroscience, leveraging its AI platforms — Lens and Next — to accelerate precision medicine.
Tempus has entered into a multi-year collaboration with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine to use Tempus’ AI-powered Lens platform for analyzing and restructuring genomic data in Alzheimer’s research. In February, Tempus also partnered with the Institute for Follicular Lymphoma Innovation to create a real-world, multimodal, deidentified FL data library in Lens, enabling AI-driven insights to accelerate follicular lymphoma treatment development and improve patient outcomes.
Meanwhile, in May, Tempus made a new strategic collaboration with Boehringer Ingelheim to advance the latter’s cancer pipeline, building on prior joint work that leveraged data and AI to drive therapeutic research and development. Furthermore, earlier this year, Tempus and Stemline Therapeutics, a Menarini Group subsidiary, announced a collaboration to advance oncology treatments. The partnership will leverage Tempus’ AI-enabled Next platform to help clinicians identify when an ESR1 test may be appropriate.
In January, Tempus joined forces with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types.
TEM’s Peers Driving Growth Through Collabs
Sophia Genetics (SOPH - Free Report) expanded its partnership with AstraZeneca (AZN - Free Report) in a multi-year collaboration to use Sophia Genetics’ multimodal AI Factories for generating evidence on breast cancer therapies’ efficacy, value and real-world impact. It will also support the development of a bespoke AI-powered predictive model to optimize outcome for patients undergoing treatment for breast cancer. Additionally, Sophia Genetics expanded its collaboration with Result Laboratorium, a leading Dutch clinical lab, to advance pharmacogenomics (PGx) insights across the region using the Sophia DDM Platform and Sophia DDM Dispatch.
AbbVie (ABBV - Free Report) announced a collaboration and license option agreement with ADARx Pharmaceuticals, a late clinical-stage biotechnology company, to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology. AbbVie also inked a license agreement with Gubra A/S to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.
TEM Stock Outperforms Industry & Benchmark
In the past year, Tempus AI shares have surged 35.9%, outperforming the industry’s 21.4% growth and the S&P 500 composite’s 15.9% improvement.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 9.38X compared with the industry average of 5.87X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's loss per share estimate has shown mixed movements for 2025 and 2026.
Image Source: Zacks Investment Research
TEM stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.